

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method for identifying a compound that inhibits angiogenesis, the method comprising the steps of:
 - (i) ~~contacting the compound with~~ determining, in the presence and absence of the compound, in vitro kinase activity of an angiogenesis polypeptide comprising an Axl polypeptide, wherein the Axl polypeptide comprises an amino acid sequence with greater than 95% identity to full length SEQ ID NO:4 and wherein the angiogenesis polypeptide has kinase activity in the absence of said compound; and
 - (ii) performing a cell-based angiogenesis phenotype assay using an endothelial cell comprising the angiogenesis polypeptide in the presence and absence of the compound, wherein inhibition of the angiogenesis polypeptide in the in vitro kinase activity and inhibition of the angiogenesis phenotype in the cell-based angiogenesis assay in the presence of the compound identifies the compound as a ~~determining the functional effect of the compound upon the angiogenesis polypeptide, thereby identifying the compound that inhibits angiogenesis.~~
- 2-11. (Cancelled)
12. (Currently amended) The method of claim 1 ~~11~~, wherein the ~~functional effect- angiogenesis phenotype is determined by measuring $\alpha v \beta 3$ expression, tube formation or~~ haptotaxis.
13. (Cancelled)
14. (Original) The method of claim 1, wherein the polypeptide is recombinant.
15. (Original) The method of claim 1, wherein the compound is an antibody.

16. (Original) The method of claim 1, wherein the compound is an antisense molecule.

17. (Original) The method of claim 1, wherein the compound is an RNAi molecule.

18. (Original) The method of claim 1, wherein the compound is a small organic molecule.

19-26. (Cancelled)

27. (Withdrawn-currently amended) An ~~in vivo~~ in vitro method for identifying a compound that inhibits angiogenesis, the method comprising the steps of:

(i) contacting the compound with a an endothelial cell that expresses an Axl polypeptide, wherein the Axl polypeptide comprises an amino acid sequence with greater than 95% identity to full length SEQ ID NO:4 and wherein down regulation of the Axl polypeptide inhibits a cell-based angiogenesis phenotype assay; and

(ii) determining the functional effect of the compound upon the Axl polypeptide, thereby identifying the compound that inhibits angiogenesis.

28-39. (Cancelled)

40. (Withdrawn) The method of claim 27, wherein the polypeptide is recombinant.

41. (Withdrawn) The method of claim 27, wherein the compound is an antibody.

42. (Withdrawn) The method of claim 27, wherein the compound is an antisense molecule.

43. (Withdrawn) The method of claim 27, wherein the compound is an RNAi molecule.

44. (Withdrawn) The method of claim 27, wherein the compound is a small organic molecule.

45-53. (Cancelled)

54. (Previously presented) The method of claim 1 or 27, wherein the Axl polypeptide comprises SEQ ID NO:4.

55. (New) The method of claim 1, wherein inhibition of the angiogenesis phenotype in the cell-based angiogenesis assay is caused by down regulation of expression of the angiogenesis polypeptide.